12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PCI-32765: Interim Phase II data

Interim data from 51 evaluable patients in the open-label, international Phase II PCYC-1104-CA trial showed that once-daily 560 mg oral PCI-32765 produced an ORR of 69%. Additionally, the ORR in patients who were naïve to treatment with Velcade bortezomib (n=31) was similar to...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >